ALLO vs. WVE, SPRY, CALT, EVO, DYN, ARDX, OCUL, BGM, AUPH, and ADPT
Should you be buying Allogene Therapeutics stock or one of its competitors? The main competitors of Allogene Therapeutics include Wave Life Sciences (WVE), ARS Pharmaceuticals (SPRY), Calliditas Therapeutics AB (publ) (CALT), Evotec (EVO), Dyne Therapeutics (DYN), Ardelyx (ARDX), Ocular Therapeutix (OCUL), Qilian International Holding Group (BGM), Aurinia Pharmaceuticals (AUPH), and Adaptive Biotechnologies (ADPT). These companies are all part of the "pharmaceutical products" industry.
Allogene Therapeutics vs.
Wave Life Sciences (NASDAQ:WVE) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment, community ranking and profitability.
Wave Life Sciences has a beta of -0.93, suggesting that its share price is 193% less volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500.
89.7% of Wave Life Sciences shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 29.1% of Wave Life Sciences shares are owned by insiders. Comparatively, 24.3% of Allogene Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Wave Life Sciences has higher revenue and earnings than Allogene Therapeutics. Wave Life Sciences is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.
Wave Life Sciences received 82 more outperform votes than Allogene Therapeutics when rated by MarketBeat users. Likewise, 67.78% of users gave Wave Life Sciences an outperform vote while only 65.89% of users gave Allogene Therapeutics an outperform vote.
Wave Life Sciences presently has a consensus target price of $22.60, suggesting a potential upside of 274.79%. Allogene Therapeutics has a consensus target price of $9.29, suggesting a potential upside of 545.06%. Given Allogene Therapeutics' higher probable upside, analysts clearly believe Allogene Therapeutics is more favorable than Wave Life Sciences.
In the previous week, Wave Life Sciences had 9 more articles in the media than Allogene Therapeutics. MarketBeat recorded 11 mentions for Wave Life Sciences and 2 mentions for Allogene Therapeutics. Wave Life Sciences' average media sentiment score of 0.91 beat Allogene Therapeutics' score of 0.00 indicating that Wave Life Sciences is being referred to more favorably in the media.
Allogene Therapeutics has a net margin of 0.00% compared to Wave Life Sciences' net margin of -66.50%. Allogene Therapeutics' return on equity of -52.13% beat Wave Life Sciences' return on equity.
Summary
Wave Life Sciences beats Allogene Therapeutics on 11 of the 19 factors compared between the two stocks.
Get Allogene Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Allogene Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ALLO) was last updated on 4/4/2025 by MarketBeat.com Staff
Buy ALLO Stock Free ALLO Stock Alerts